Key result
AT1a receptor deficiency or pharmacological blockade significantly impaired ischemia-induced angiogenesis and blood flow recovery in mice compared to wild-type controls.
Why the study?
Does AT1a receptor deficiency or blockade impair ischemia-induced angiogenesis in a mouse model of hindlimb ischemia?
Does AT1a receptor deficiency or blockade impair ischemia-induced angiogenesis in a mouse model of hindlimb ischemia?
The angiotensin II type 1 receptor pathway promotes early ischemia-induced angiogenesis by supporting inflammatory cell infiltration and angiogenic cytokine expression.
Answers are grounded in this paper and cite their sources.
AT1a signaling may support ischemia-induced angiogenesis in mice; hypothesis-generating and should not change ARB use in patients.
The role of the renin-angiotensin system (RAS) in angiogenesis is little known. Here, we show that the angiotensin II (ATII) type 1 (AT1) receptor plays an important role in ischemia-induced angiogenesis. Well-developed collateral vessels and angiogenesis were observed in wild-type (WT) mice in response to hindlimb ischemia, whereas these responses were reduced in ATII type 1a receptor knockout (AT1a–/–) mice. Ischemia-induced angiogenesis was also impaired in WT mice treated with the AT1 receptor blocker TCV-116. These effects were not due to reduced systemic blood pressure (SBP), because hydralazine treatment preserved angiogenesis in WT mice although it reduced SBP to a level similar to that of AT1a–/– mice. Infiltration of inflammatory mononuclear cells (MNCs), including macrophages and T lymphocytes, was suppressed in the ischemic tissues of AT1a–/– mice compared with WT mice. Double immunofluorescence staining revealed that infiltrated macrophages and T lymphocytes expressed VEGF, and the expression of VEGF and monocyte chemoattractant protein-1 was also decreased in AT1a–/–. Finally, the impaired angiogenesis in AT1a–/– mice was rescued by intramuscular transplantation of MNCs obtained from WT mice, further indicating the importance of MNC infiltration in ischemia-induced angiogenesis. Thus, the ATII–AT1 receptor pathway promotes early angiogenesis by supporting inflammatory cell infiltration and angiogenic cytokine expression.
No takes yet. Share an insight, caveat, or question.
Sasaki et al. (2002) studied Hindlimb ischemia. AT1a receptor deficiency (knockout) or AT1 receptor blockade vs. Wild-type (WT) mice was evaluated on Ischemic/normal hindlimb blood flow ratio (LDBF ratio) (p=<0.05). AT1a receptor deficiency or pharmacological blockade significantly impaired ischemia-induced angiogenesis and blood flow recovery in mice compared to wild-type controls.
Synapse has enriched 10 related papers. Consider them for comparative context: